Meeting
2012 ASCO Annual Meeting
Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706.
Authors
Makoto Tahara
National Cancer Center Hospital East, Kashiwa, Japan
Makoto Tahara , Naomi Kiyota , Junki Mizusawa , Kenichi Nakamura , Ryuichi Hayashi , Tetsuo Akimoto , Yasuhisa Hasegawa , Shigemichi Iwae , Nobuya Monden , Kazuto Matsuura , Hirofumi Fujii , Yusuke Onozawa , Akihiro Homma , Akira Kubota , Haruhiko Fukuda , Masato Fujii
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
000001272
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5542)
DOI
10.1200/jco.2012.30.15_suppl.5542
Abstract #
5542
Poster Bd #
22B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
First Author: Chunmei Bai
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2022 ASCO Annual Meeting
Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.
First Author: Vanita Noronha